# Phase 2 Study of Dacomitinib in NSCLC

> **NCT04027647** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 118 (actual)

## Conditions studied

- NSCLC Stage IIIB
- NSCLC Stage IIIC
- NSCLC Stage IV
- Recurrent NSCLC
- EGFR Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04027647
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-11
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04027647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04027647, "Phase 2 Study of Dacomitinib in NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04027647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*